Mayo Clinic Proceedings
ROCHESTER, Minn. -- Myocarditis is an important, and often unrecognized cause of dilated cardiomyopathy (DCM).
WILMINGTON, Del. -- Aug. 26, 2009 -- Mayo Clinic Proceedings published a peer-reviewed comparative effectiveness study performed by HealthCore, Inc. in its August edition. The study demonstrated that asthma patients in general had better clinical outcomes with oral controllers than inhaled corticosteroids.
ROCHESTER, Minn. -- A symptomless blood disorder, monoclonal gammopathy of undetermined significance, known as MGUS, is not linked to as many serious diseases as previously thought. This finding may save patients from undergoing unnecessary workup and treatment according to a study published in the August 2009 issue of Mayo Clinic Proceedings.
Chemical dependency and recovery in patients and physicians are closely examined in a series of articles and editorials in the July 2009 issue of Mayo Clinic Proceedings. The subject is especially timely. As the immense challenges, including potential tragedies, of prescription chemical addiction and abuse are being discussed, these articles offer crucial overview, direction and optimism.
ROCHESTER, Minn. -- Patients living with migraine have strong reason for new optimism concerning a positive future. Two review articles and an accompanying editorial, "The Future of Migraine: Beyond Just Another Pill," in the current issue of Mayo Clinic Proceedings, are the basis for an ironic premise.
ROCHESTER, Minn. -- A new study conducted at Mayo Clinic reports that one in six patients receiving therapeutic doses of certain drugs for Parkinson's disease develops new-onset, potentially destructive behaviors, notably compulsive gambling or hypersexuality.
When patients choose to leave the hospital before the treating physician recommends discharge, the consequences may involve risk of inadequately treated medical conditions and the need for readmission, according to a review in the March 2009 issue of Mayo Clinic Proceedings.
A new study outlines how strictly controlling the levels of glucose, or sugar, in a patient's blood can increase the survival rate of critically ill patients. ''This is a low-cost, effective intervention that can profoundly affect patients,'' said the study's author. ''Intensive glucose management will eventually become a standard of care in ICUs (intensive care units) worldwide.''
A long-term study of patients in Rochester, Minn., with the eating disorder anorexia nervosa found that their survival rates did not differ from the expected survival rates of others of the same age and sex. The results, published in the March issue of Mayo Clinic Proceedings, add to the knowledge of anorexia nervosa and point to other areas that need greater study from researchers. "Although our data suggest that overall mortality is not increased among community patients with anorexia nervosa in general, these findings should not lead to complacency in clinical practice because deaths do occur," says L. Joseph Melton, III, M.D., Mayo Clinic epidemiologist and an author of the report.
Nearly one-third of patients with advanced multiple myeloma who had failed current standard therapy of chemotherapy or stem cell transplantation responded to thalidomide for a median duration of nearly one year in a Mayo Clinic study of the effects of thalidomide on myeloma. The findings are reported in the January issue of Mayo Clinic Proceedings.
Many studies in the last three years have determined that thalidomide is effective in the treatment of multiple myeloma, following the initial report by researchers at the University of Arkansas. However, information is limited on how long thalidomide therapy works and on survival rates with such therapy.
Gastroenterologists at Mayo Clinic in Jacksonville, Fla., report photodynamic therapy (PDT) appears to destroy the abnormal tissue of Barrett's esophagus as well as superficial esophageal cancer. Here's how PDT works. Patients are given an injection of a photosensitizing drug called porfimer sodium (Photofrin). Cells in the body absorb this drug. Normal cells get rid of it, but the drug tends to collect in premalignant and malignant cells. Two days after the injection of Photofrin, physicians insert and endoscope into the sedated patient's esophagus. An endoscope is a thin, flexible tube with a miniature camera on its tip. Physicians deliver a specific wavelength of red laser light through the endoscope to the targeted cells. The laser light destroys the Photofrin-containing cells. Normal esophageal cells grow back in their place.
Researchers from the Mayo Clinic say that wearing ionized bracelets for the treatment of muscle and joint pain is no more effective than wearing placebo bracelets. Authors of the published study randomly assigned 305 participants to wear an ionized bracelet for 28 days and another 305 participants to wear a placebo bracelet for the same duration. The study volunteers were men and women 18 and older who had self-reported musculoskeletal pain at the beginning of the study. Neither the researchers nor the participants knew which volunteers wore an ionized bracelet and which wore a placebo bracelet. Bracelets were worn according to the manufacturer's recommendations. Both types of bracelets were identical and were supplied by the manufacturer, QT, Inc.
